Statement on FDA Removal of Blackbox Warnings on Estrogen-Based Hormone Therapy Products for Menopause

As a leading voice in women’s midlife health, HealthyWomen recognizes the important step taken by the FDA to improve access to hormone therapy (HT) products for women experiencing perimenopausal and menopausal symptoms by modifying the black box warning labels for estrogen products. Since 2003, the blackbox warning on low-dose vaginal estrogen products has had a chilling effect on patients and clinicians alike, undermining the use of this proven treatment for genitourinary syndrome of menopause. HealthyWomen is proud to have called for the removal of this blackbox warning on low-dose vaginal e